Vargatef is under clinical development by Boehringer Ingelheim International and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vargatef’s likelihood of approval (LoA) and phase transition for Cervical Cancer took place on 27 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vargatef Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vargatef overview

Nintedanib (Vargatef) is an indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. It is formulated as soft gelatin capsules for oral route of administration. Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor histology after first-line chemotherapy.

Nintedanib (BIBF 1120, Vargatef) is under development for the treatment of advanced carcinoid tumors, non-small cell lung cancer, fibrosing interstitial lung disease, urothelial carcinoma,  cervical carcinoma, interstitial lung fibrosis, systemic sclerosis associated interstitial lung disease and progressive fibrosing interstitial lung disease. It is administered orally and as an intravenous infusion. It targets VEGFR 1-3, PDGFR alpha, and beta, FGFR 1-3), (Flt)-3, Lck and Src. It was also under development for the treatment of glioblastoma multiforme (GBM), high-grade glioma, prostate cancer and refractory or relapsed multiple myeloma. The drug candidate is a new chemical entity (NCE). The drug candidate was under development for malignant pleural mesothelioma, medullary thyroid cancer,advanced hepatocellular carcinoma, ovarian cancer, breast cancer, endometrial cancer, fallopian tube or primary peritoneal cancer, BRAF wild type metastatic melanoma, small-cell lung cancer, non-small cell cancer with squamous cell histology, advanced or metastatic colorectal cancer, renal cell carcinoma, inflammatory breast cancer, appendiceal carcinoma, lung adenocarcinoma, soft tissue sarcoma, Brenner tumor, relapsed or refractory acute myeloid leukemia, esophagogastric cancer, and neuroendocrine tumors.

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Quick View Vargatef LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Vargatef
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.